Estrella Immunopharma (Nasdaq:ESLA) - Stock Price, News & Analysis

ESLA Stock Overview

A clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. More details

ESLA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Earnings have declined by 39.2% per year over past 5 years

Highly volatile share price over the past 3 months compared to the US market

+ 2 more risks

Estrella Immunopharma, Inc. Competitors

LianBio

OTCPK:LIAN.Y

US$31.4m

Lantern Pharma

NasdaqCM:LTRN

US$33.8m

Neoleukin Therapeutics

NasdaqCM:NLTX

US$32.8m

AgeX Therapeutics

NYSEAM:AGE

US$31.5m

Price History & Performance

Summary of all time highs, changes and price drops for Estrella Immunopharma
Historical stock prices
Current Share Price	US$1.01
52 Week High	US$3.23
52 Week Low	US$0.63
Beta	0.24
11 Month Change	12.22%
3 Month Change	-14.41%
1 Year Change	-32.21%
33 Year Change	-89.88%
5 Year Change	n/a
Change since IPO	-89.64%

Recent updates

Companies Like Estrella Immunopharma (NASDAQ:ESLA) Are In A Position To Invest In Growth

Oct 09

Shareholder Returns

	ESLA	US Biotechs	US Market
7D	18.7%	4.0%	2.2%
1Y	-32.2%	18.3%	32.6%

Return vs Industry: ESLA underperformed the US Biotechs industry which returned 18.3% over the past year.

Return vs Market: ESLA underperformed the US Market which returned 32.6% over the past year.

Price Volatility

Is ESLA's price volatile compared to industry and market?
ESLA volatility
ESLA Average Weekly Movement	16.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ESLA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ESLA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2006	n/a	Cheng Liu	www.estrellabio.com

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.

Estrella Immunopharma, Inc. Fundamentals Summary

How do Estrella Immunopharma's earnings and revenue compare to its market cap?
ESLA fundamental statistics
Market cap	US$36.19m
Earnings (TTM)	-US$8.82m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Is ESLA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ESLA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$8.82m
Earnings	-US$8.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.24
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ESLA perform over the long term?

See historical performance and comparison

Estrella Immunopharma NasdaqCM:ESLA Stock Report